北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 北京大学肝病研究所  > 期刊论文
学科主题: 临床医学
题名:
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naive Patients Infected with Genotype 1b Hepatitis C Virus
作者: Wang, Ye; Rao, Hui-Ying; Xie, Xing-Wang; Wei, Lai
关键词: Antiviral Resistance ; Direct Antiviral Agents ; Hepatitis C Virus
刊名: CHINESE MEDICAL JOURNAL
发表日期: 2015-10-05
DOI: 10.4103/0366-6999.166038
卷: 128, 期:19, 页:2625-2631
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal
研究领域[WOS]: General & Internal Medicine
关键词[WOS]: NS3 PROTEASE INHIBITORS ; FIXED-DOSE COMBINATION ; INTERFERON-ALPHA 2A ; PEGYLATED INTERFERON ; PLUS RIBAVIRIN ; NS5A INHIBITOR ; OPEN-LABEL ; VIROLOGICAL ESCAPE ; DRUG-RESISTANCE ; PHASE-2 TRIAL
英文摘要:

Background: It has been reported that several baseline polymorphisms of direct-acting antivirals (DAAs) agents resistance-associated variants (RAVs) would affect the treatment outcomes of patients chronically infected with hepatitis C virus (CHC). The aim of this study is to investigate the prevalence of DAAs RAVs in treatment-naive GT1b CHC patients.

Methods: Direct sequencing and ultra-deep sequencing of the HCV NS3, NS5A, and NS5B gene were performed in baseline serum samples of treatment-naive patients infected with genotype 1b hepatitis C virus (HCVs).

Results: One hundred and sixty CHC patients were studied. Complete sequence information was obtained for 145 patients (NS3), 148 patients (NS5A), and 137 patients (NS5B). Treatment-failure associated variants of DAAs were detected: 56.6% (82/145) of the patients presented S122G for simeprevir (NS3 protease inhibitor); 10.1% (14/148) of the patients presented Y93H for daclatasvir and ledipasvir (NS5A protein inhibitors); 94.2% (129/137) of the patients presented C316N for sofosbuvir (NS5B polymerase inhibitor). Nearly, all of the DAAs RAVs detected by ultra-deep sequencing could be detected by direct sequencing.

Conclusions: The majority of genotype 1b CHC patients in China present a virus population carrying HCV DAAs RAVs. Pretreatment sequencing of HCV genome might need to be performed when patients infected with GT1b HCV receiving DAAs-containing regimens in China. Population sequencing would be quite quantified for the work.

语种: 英语
所属项目编号: 2008ZX10002-013 ; 2008ZX10002-012 ; 2012ZX10002003
项目资助者: China National Science and Technology Major Project for Infectious Diseases Control
WOS记录号: WOS:000362853100012
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/64738
Appears in Collections:北京大学第二临床医学院_北京大学肝病研究所_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Peoples Hosp, Inst Hepatol, Beijing Key Lab Hepatitis & Immunotherapy Liver D, Beijing 100044, Peoples R China

Recommended Citation:
Wang, Ye,Rao, Hui-Ying,Xie, Xing-Wang,et al. Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naive Patients Infected with Genotype 1b Hepatitis C Virus[J]. CHINESE MEDICAL JOURNAL,2015,128(19):2625-2631.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wang, Ye]'s Articles
[Rao, Hui-Ying]'s Articles
[Xie, Xing-Wang]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wang, Ye]‘s Articles
[Rao, Hui-Ying]‘s Articles
[Xie, Xing-Wang]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace